Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 22 annual H.C. Wainwright Global Investment Conference on Monday, September 14, 2020 at 9:30 a.m. ET. The...

BCRX : 3.61 (+5.25%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 22 newly-hired employees inducement options to purchase an aggregate...

BCRX : 3.61 (+5.25%)
U.S. Government Exercises Option To Purchase Additional RAPIVAB(R) from BioCryst for Delivery to Strategic National Stockpile

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst's approved...

BCRX : 3.61 (+5.25%)
Thinking about buying stock in Gogo Inc, J.Jill Inc, Westport Fuel Systems, BioCryst Pharmaceuticals, or Uber Technologies?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOGO, JILL, WPRT, BCRX, and UBER.

BCRX : 3.61 (+5.25%)
GOGO : 9.19 (+3.49%)
JILL : 0.5369 (-4.14%)
UBER : 34.13 (+2.34%)
WPRT : 1.5650 (-2.19%)
NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst a new...

BCRX : 3.61 (+5.25%)
FDA Grants Orphan Drug Designation for BCX9930 in PNH

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its oral Factor D inhibitor, BCX9930, for the treatment...

BCRX : 3.61 (+5.25%)
SmarTrend Watching for Potential Pullback in Shares of Biocryst Pharm After 11.84% Gain

Biocryst Pharm (NASDAQ:BCRX) traded in a range yesterday that spanned from a low of $4.23 to a high of $4.49. Yesterday, the shares gained 11.8%, which took the trading range above the 3-day high of...

BCRX : 3.61 (+5.25%)
Thinking about buying stock in Sorrento Therapeutics, FAT Brands, BioCryst Pharmaceuticals, TOP Ships, or Tesla?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, FAT, BCRX, TOPS, and TSLA.

BCRX : 3.61 (+5.25%)
SRNE : 9.53 (+3.70%)
Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?

Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.

BCRX : 3.61 (+5.25%)
Encompass Health's (EHC) Expansion Plans Continue in Florida

Encompass Health (EHC) continues to expand in Florida via hospitals in order to offer improved health services in the state.

BCRX : 3.61 (+5.25%)
QDEL : 194.71 (+1.43%)
KIN : 4.52 (-2.16%)
EHC : 61.55 (+0.41%)
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Misses Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of 14.29% and -9.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BCRX : 3.61 (+5.25%)
BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones

--ORLADEYO (berotralstat) approvals expected in U.S. and Japan in Q4 2020, EU in early 2021--

BCRX : 3.61 (+5.25%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 20 newly-hired employees inducement options to purchase an aggregate...

BCRX : 3.61 (+5.25%)
FDA Grants Fast Track Designation for BCX9930 in PNH

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral Factor D inhibitor, BCX9930, for the treatment...

BCRX : 3.61 (+5.25%)
Encompass Health Continues to Strengthen Presence in Florida

Encompass Health (EHC) intends to offer improved health outcomes through plans to construct a new hospital in Florida, where it already boasts of a strong base.

BCRX : 3.61 (+5.25%)
ACHC : 27.66 (+0.66%)
AKBA : 2.50 (+1.63%)
EHC : 61.55 (+0.41%)
Watch for Biocryst Pharm to Potentially Pullback After Gaining 3.16% Yesterday

Biocryst Pharm (NASDAQ:BCRX) traded in a range yesterday that spanned from a low of $4.10 to a high of $4.32. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $4.21...

BCRX : 3.61 (+5.25%)
After Yesterday's Decline of 2.17%, Biocryst Pharm Offers Investors Better Value

Biocryst Pharm (NASDAQ:BCRX) traded in a range yesterday that spanned from a low of $3.91 to a high of $4.21. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $4.08...

BCRX : 3.61 (+5.25%)
Implied Volatility Surging for BioCryst (BCRX) Stock Options

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

BCRX : 3.61 (+5.25%)
Galidesivir Stops Zika Viral Replication in Primate Model

--Data published in Science Translational Medicine--

BCRX : 3.61 (+5.25%)
BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has established an expanded access program (EAP) with oral, once-daily berotralstat, an investigational drug, for patients...

BCRX : 3.61 (+5.25%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar